These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 22988353)

  • 1. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma.
    Bose D; Das RN; Chatterjee U; Banerjee U
    Indian J Med Paediatr Oncol; 2012 Apr; 33(2):107-11. PubMed ID: 22988353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytokeratin subtypes in thyroid tumours: immunohistochemical study with emphasis on the follicular variant of papillary carcinoma.
    Cameron BR; Berean KW
    J Otolaryngol; 2003 Oct; 32(5):319-22. PubMed ID: 14974863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions.
    Sadiq Q; Sekhri R; Dibaba DT; Zhao Q; Agarwal S
    World J Surg Oncol; 2021 May; 19(1):143. PubMed ID: 33964951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical diagnosis of papillary thyroid carcinoma.
    Cheung CC; Ezzat S; Freeman JL; Rosen IB; Asa SL
    Mod Pathol; 2001 Apr; 14(4):338-42. PubMed ID: 11301350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution.
    Sahoo S; Hoda SA; Rosai J; DeLellis RA
    Am J Clin Pathol; 2001 Nov; 116(5):696-702. PubMed ID: 11710686
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid.
    Erkiliç S; Aydin A; Koçer NE
    Endocr Pathol; 2002; 13(3):207-11. PubMed ID: 12446919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CK19 IS A USEFUL MARKER IN DISTINGUISHING FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA FROM BENIGN THYROID LESIONS WITH FOLLICULAR GROWTH PATTERN.
    Noroozinia F; Gheibi A; Ilkhanizadeh B; Abbasi A
    Acta Endocrinol (Buchar); 2016; 12(4):387-391. PubMed ID: 31149120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
    Abouhashem NS; Talaat SM
    Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of cytokeratin 19 in the cytosolic fraction of thyroid lesions: ELISA and Western blot analysis.
    Krzeslak A; Gaj Z; Pomorski L; Lipinska A
    Mol Med Rep; 2008; 1(4):565-9. PubMed ID: 21479451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility.
    Baloch ZW; Abraham S; Roberts S; LiVolsi VA
    Hum Pathol; 1999 Oct; 30(10):1166-71. PubMed ID: 10534163
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid.
    El Demellawy D; Nasr A; Alowami S
    Diagn Pathol; 2008 Feb; 3():5. PubMed ID: 18254952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Follicular adenoma with papillary architecture: a lesion mimicking papillary thyroid carcinoma.
    Mai KT; Landry DC; Thomas J; Burns BF; Commons AS; Yazdi HM; Odell PF
    Histopathology; 2001 Jul; 39(1):25-32. PubMed ID: 11454041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD56, HBME-1 and cytokeratin 19 expressions in papillary thyroid carcinoma and nodular thyroid lesions.
    Erdogan-Durmus S; Ozcan D; Yarikkaya E; Kurt A; Arslan A
    J Res Med Sci; 2016; 21():49. PubMed ID: 27904595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic Value of TROP-2 and CK19 Expression in Papillary Thyroid Carcinoma in Both Surgical and Cytological Specimens.
    Abdou AG; Shabaan M; Abdallha R; Nabil N
    Clin Pathol; 2019; 12():2632010X19863047. PubMed ID: 31384753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fine-needle aspiration biopsy of papillary thyroid carcinoma: diagnostic utility of cytokeratin 19 immunostaining.
    Nasser SM; Pitman MB; Pilch BZ; Faquin WC
    Cancer; 2000 Oct; 90(5):307-11. PubMed ID: 11038428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of cytokeratin 19 in the diagnosis of thyroid papillary carcinoma by quantitative polymerase chain reaction.
    Flanagan JN; Pineda P; Knapp PE; De Las Morenas A; Lee SL; Braverman LE
    Endocr Pract; 2008 Mar; 14(2):168-74. PubMed ID: 18308654
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Expression of cytokeratin19, galectin-3 and HBME-1 in thyroid lesions and their differential diagnoses].
    Teng XD; Wang LJ; Yao HT; Li J; Ding W; Yan LP
    Zhonghua Bing Li Xue Za Zhi; 2004 Jun; 33(3):212-6. PubMed ID: 15256110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic significance of CK19, RET, galectin-3 and HBME-1 expression for papillary thyroid carcinoma.
    Zhu X; Sun T; Lu H; Zhou X; Lu Y; Cai X; Zhu X
    J Clin Pathol; 2010 Sep; 63(9):786-9. PubMed ID: 20644217
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Expression of Twist in papillary thyroid carcinomas and its roles in differential diagnosis].
    He CN; He L; Cheng JQ; Chen SC; Zhao HF; Zhai JP; Zhang J
    Zhonghua Bing Li Xue Za Zhi; 2008 Jan; 37(1):35-9. PubMed ID: 18509983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical study of papillary thyroid carcinoma and possible papillary thyroid carcinoma-related benign thyroid nodules.
    Mai KT; Ford JC; Yazdi HM; Perkins DG; Commons AS
    Pathol Res Pract; 2000; 196(8):533-40. PubMed ID: 10982016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.